Login or sign up
For business

Prior Authorization Accountability

4.0· 5 reviews
Average ratingGreat
4.0/ 5

Based on 5 reviews

540%
440%
30%
220%
10%
Ask AI

Questions about Prior Authorization Accountability

Based on 5 reviews, listing data and website checks · updated 3 days ago

What is Prior Authorization Accountability?

Prior Authorization Accountability is a United States-based research and advocacy project that quantifies the population-level excess cancer mortality risk associated with insurance prior-authorization delays. It presents an evidence-based model built on peer-reviewed dose-response data, including a meta-analysis showing roughly a 10% higher relative risk of death for each four-week delay in starting cancer treatment. The site offers a calculator, an insurer dashboard, and three fully sourced scenarios, displaying estimates with 95% confidence intervals and full methodology.

How does the model estimate mortality risk?

The project connects peer-reviewed mortality data with published plan delay figures to estimate excess mortality risk. It explicitly states that it does not attribute specific deaths to individual companies, only estimating population-level excess risk from each plan's own published delay data. Estimates are clearly labeled as estimates and are not medical or legal advice.

How does the calculator work?

Users can enter a real delay length and indication into the calculator to get an estimated excess-mortality multiplier with a 95% confidence interval. The calculator uses the verified HR^(days/28) formula based on peer-reviewed hazard ratios from a meta-analysis of 34 studies. This allows anyone to see the measurable cost of delays using published association data.

What features does the insurer dashboard offer?

The insurer dashboard allows users to sort indications and published plan delay figures side by side. Every row carries its source and flags intervals that cross 1.0, providing transparency on how delays translate into mortality risk. This tool helps visualize the connection between plan metrics and peer-reviewed mortality curves.

What are the press-ready verified cases?

The project provides three fully sourced scenarios plus the Harm Bridge, which maps plan delay to peer-reviewed mortality risk. These include copy-paste summaries designed for reporters to use in press-ready verified cases. The scenarios demonstrate how to move from a published delay to a transparent estimate.

How does the methodology ensure accuracy?

The methodology starts from a plan's own reported decision time or appeal turnaround, the kind of figure required under the federal interoperability and prior-authorization rule (CMS-0057-F). This ensures the estimates are grounded in actual metrics insurers are required to publish. The process then maps that delay onto the dose-response hazard ratios from the meta-analysis.

What do physician surveys indicate about adverse events?

The project estimates that 29% of physicians report prior authorization led to a serious adverse event, such as hospitalization, disability, or death. Additionally, 7% of radiation oncologists say prior authorization has led to or contributed to a patient's death. These figures come from the AMA 2024 Prior Authorization Physician Survey and ASTRO 2024 Prior Authorization Survey.

Where is the business located and what industry does it serve?

The project is located in the United States and operates as a non-profit organization management entity within the hospital and health care industry. It focuses on research and advocacy to highlight the measurable cost of delays in cancer treatment. The team works to provide transparent estimates for public accountability and policy discussion.

How can users contribute their experiences?

The project offers a 'Share Your Story' feature where patients and clinicians can document a prior-authorization delay. This allows for public accountability and policy discussion based on real experiences. The feature is available for anyone who wants to contribute their story with consent.

What is the core mission of the project?

The project is built on the premise that delays have a measurable cost and that peer-reviewed data lets us estimate this risk transparently. It aims to connect the harm reported by clinicians with the mortality risk measured by meta-analyses. This connection helps stakeholders understand the true impact of prior-authorization processes.

What is the official website of Prior Authorization Accountability?

The official website of Prior Authorization Accountability is authcal.xyz.

How is Prior Authorization Accountability rated on Trustburn?

On Trustburn, Prior Authorization Accountability has a rating of 4 out of 5 based on 5 reviews.

AI-generated from reviews on this page. Verify anything important with the company directly.

David Chen
Reviews 1

The calculator is a convenient way to estimate mortality risk from delay data. I appreciate the clear source citations. However, the interface could be more intuitive for quick comparisons. Overall, it is a useful resource for understanding the scale of the problem in prior authorization.

Sarah Jenkins
Reviews 1

The project effectively bridges clinical data with administrative metrics. By applying hazard ratios to published delay figures, the team provides a quantifiable view of risk. The use of confidence intervals adds necessary statistical rigor. It is impressive how the dashboard aligns plan data with peer-reviewed mortality curves. This approach allows for a more nuanced understanding of how prior authorization affects cancer treatment outcomes. The evidence section is particularly strong, citing established medical literature. For researchers, the transparency in methodology is a significant asset.

Marcus Thorne
Reviews 1

I have been looking for a reliable way to quantify the impact of prior authorization delays on patient outcomes, and this project seems to hit the mark. The connection between the Hanna et al. data and the insurer dashboards is well explained. It is reassuring to see confidence intervals attached to the estimates rather than just raw numbers. The methodology feels rigorous, especially since it relies on peer-reviewed sources like the BMJ study. I am curious if the calculator allows for custom delay inputs beyond standard four-week increments, or if it strictly adheres to the formula based on the published delay data. Also, does the dashboard update in real time as new plan data becomes available under the CMS rule? For someone trying to understand the broader scope of these delays, the evidence section is particularly helpful. It grounds the abstract concept of risk in actual published studies. I would like to know if there is a way to export the data for further analysis, or if it is primarily for public viewing. The distinction between correlation and causation is handled well. Still, knowing the update frequency would be useful.

Elena Vance
Reviews 1

Prior Authorization Accountability offers a transparent way to see how delays impact cancer treatment outcomes. The link between published delay figures and mortality risk is easy to follow. This tool helps clarify the real cost of administrative hold-ups for patients and policymakers alike.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Prior Authorization Accountability

Prior Authorization Accountability is a United States–based research and advocacy project that quantifies the population-level excess cancer mortality risk associated with insurance prior-authorization delays. It presents an evidence-based model built on peer-reviewed dose-response data, including a meta-analysis showing roughly a 10% higher relative risk of death for each four-week delay in starting cancer treatment. The site offers a calculator, an insurer dashboard, and three fully sourced scenarios, displaying estimates with 95% confidence intervals and full methodology. It explicitly states that it does not attribute specific deaths to individual companies, does not provide medical or legal advice, and never claims a named insurer caused a specific number of deaths.